Glucagon-like peptide-1 receptor agonists:Exploring the mechanisms from glycemic control to treatment of multisystemic diseases
作者机构：Department of CardiologySouthwest Medical UniversityLuzhou 646000Sichuan ProvinceChina School of Basic Medical SciencesSouthwest Medical UniversityLuzhou 646000Sichuan ProvinceChina Department of EndocrinologyThe Affiliated Hospital of Chengde Medical CollegeChengde 067000Hebei ProvinceChina Department of CardiologyThe Affiliated Hospital of Southwest Medical UniversityLuzhou 646000Sichuan ProvinceChina Key Laboratory of Medical ElectrophysiologyMinistry of EducationInstitute of Cardiovascular ResearchBasic Medicine Research Innovation Center for Cardiometabolic DiseasesMinistry of EducationNucleic Acid Medicine of Luzhou Key LaboratorySouthwest Medical UniversityLuzhou 646000Sichuan ProvinceChina
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2024年第30卷第36期
页 面：4036-4043页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Supported by National Natural Science Foundation of China,No.U23A20398 and No.82030007 Sichuan Science and Technology Program,No.2022YFS0578
主 题：Glucagon-like peptide-1 receptor agonists Glycemic control Multisystem diseases Mechanism of action Cardiovascular protection Renal disease Bone metabolism Non-alcoholic fatty liver disease Neuroprotection Polycystic ovary syndrome
摘 要：This editorial takes a deeper look at the insights provided by Soresi and Giannitrapani,which examined the therapeutic potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)for metabolic dysfunction-associated fatty liver *** provide supplementary insights to their research,highlighting the broader systemic implications of GLP-1RAs,synthesizing the current understanding of their mechanisms and the trajectory of research in this ***-1RAs are revolutionizing the treatment of type 2 diabetes mellitus and *** glycemic control,GLP-1RAs demonstrate cardiovascular and renal protective effects,offering potential in managing diabetic kidney disease alongside renin–angiotensin–aldosterone system *** role in bone metabolism hints at benefits for diabetic osteoporosis,while the neuroprotective properties of GLP-1RAs show promise in Alzheimer s disease treatment by modulating neuronal insulin ***,they improve hormonal and metabolic profiles in polycystic ovary *** editorial highlights the multifaceted mechanisms of GLP-1RAs,emphasizing the need for ongoing research to fully realize their therapeutic potential across a range of multisystemic diseases.
维普期刊数据库